Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR-NK Cells in Relapsed/Resistant B-ALL
NCT06631040Phase 2Not yet recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Dec 2024
- Primary completion
- Nov 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Anti-CD19 CAR-NK cells in acute lymphoblastic leukemia (ALL), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Incidence of dose-limiting toxicity at 4 weeks, Maximum Tolerated Dose at 4 weeks and 1 more. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
Anti-CD19 CAR-NK cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06631040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06631040.